Seeking Alpha

jimmy Turano » Comments » ASD

  • Jim Cramer's Mad Money Lightning Round Picks, 8/3/07 [View article]
    August 8th
    The stock has moved way too much on RNAi hype and very early pre-clinical and Phase I data for big targets such as obesity. They just raised a lot of money, hit the stock price, and they are going to have to do it again in a
    year or so at the rate they are burning money. The company will have to
    strike a major deal to see a major upside move in the stock. A
    marketing deal, that is -- big Pharma does not buy drug delivery companies.
    I believe fund managers are taking advantage of 19 Touts by Cramer then
    will short the stock and cash in Big time. Maybe not a conspiracy but shareholders are left in the dust all the time!
    Their statistics page is a disaster and they have to jump many hurdles with RNAI with FDA, Good Luck, you get what you pay for. NO PRODUCTS!
    Aug 08 10:15 am |Rating: 0 0 |Link to Comment
  • Jim Cramer's Mad Money Lightning Round Picks, 8/3/07 [View article]
    Aug.6th,2007 Cramer touts NSTK for the 19th time but who's counting!
    Yea buy it before Wednesday's dismal earnings report.
    You want a good chance of speculation with a company that boasts a better statistics page than NSTK, then buy VPHM. It will do far better in next 10months than nstk.
    Overpriced stock nstk compared to sales!
    Other companies are doing well in phase trials with obesity and nstk is just what Cramer says"HOPE"
    All I know is I HOPE you purchase something else because nstk is not what it appears to be in my opinion!
    Aug 06 10:30 am |Rating: 0 0 |Link to Comment
More on ASD by jimmy Turano
Comments by Ticker
A, AA, AAPL, ABK, ABPIQ.PK, ABT, ABX, ACAD, ACCP.OB, ACOR, ACTC.PK, ACTU, ADAT, ADLS, ADLS.OB, AEM, AET, AEZS, AGEN, AGN, AGU, AIB, AIR, AIS, AKS, AL, ALKS, ALL, ALNY, ALPMF.PK, ALTH, ALTR, ALXN, AMAG, AMGN, AMLN, AMP, AMZN, ANDS, ANPI, AOB, APA, APOL, APWR, ARAY, ARDM.OB, ARIA, ARNA, ARQL, ARRY,
jimmy Turano's
Comments Stats
298 comments
Rating: 91 (201 - 110 )